Geschatte realtime
Cboe BZX
17:21:20 01-07-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
33,47
USD
|
-4,37%
|
|
+31,41%
|
0,00%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
62,06
|
188
|
257,9
|
320,7
|
531,8
|
EBITDA
1 |
-104,8
|
-163,5
|
-214,6
|
-238,7
|
-155,8
|
Bedrijfsresultaat (EBIT)
1 |
-119,8
|
-186,6
|
-238,5
|
-269,1
|
-189,1
|
Operationele Marge
|
-193,02%
|
-99,23%
|
-92,49%
|
-83,93%
|
-35,56%
|
Resultaat voor belastingen (EBT)
1 |
-115
|
-209,9
|
-259,2
|
-289,7
|
-213,8
|
Nettowinst (verlies)
1 |
-115
|
-209,9
|
-259,2
|
-289,8
|
-214,1
|
Nettomarge
|
-185,23%
|
-111,62%
|
-100,52%
|
-90,38%
|
-40,26%
|
WPA
|
-
|
-4,033
|
-4,728
|
-5,298
|
-4,201
|
Free Cash Flow
|
-
|
-140
|
-122,1
|
-120,7
|
-105,9
|
FCF-marge
|
-
|
-74,46%
|
-47,37%
|
-37,63%
|
-19,91%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
1/09/21
|
1/09/21
|
27/04/22
|
25/08/23
|
20/05/24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
130
|
291
|
Nettokaspositie
1 |
225
|
262
|
38,7
|
-
|
-
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-0,5449
x
|
-1,865
x
|
Free Cash Flow
|
-
|
-140
|
-122
|
-121
|
-106
|
ROE (netto-inkomsten/eigen vermogen)
|
-
|
-66%
|
-119%
|
4.797%
|
113%
|
ROA (netto-inkomsten/totale activa)
|
-
|
-20,8%
|
-23,2%
|
-28,9%
|
-19,8%
|
Totale activa
1 |
-
|
1.010
|
1.116
|
1.002
|
1.083
|
Nettoactief per aandeel
|
-
|
-8,150
|
-12,80
|
-17,80
|
-21,80
|
Cashflow per aandeel
|
-
|
8,150
|
4,410
|
4,790
|
2,610
|
Capex
1 |
17
|
13,4
|
11,8
|
18,4
|
34,6
|
Capex/omzet
|
27,45%
|
7,14%
|
4,56%
|
5,73%
|
6,51%
|
Datum van publicatie
|
1/09/21
|
1/09/21
|
27/04/22
|
25/08/23
|
20/05/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| 0,00% | 5,77 mld. | | +18,39% | 45,51 mld. | | -8,79% | 38,52 mld. | | +37,94% | 38,13 mld. | | +27,11% | 30,74 mld. | | -8,64% | 26,03 mld. | | +12,44% | 25,92 mld. | | +47,63% | 14,13 mld. | | +34,92% | 12,73 mld. | | -6,85% | 11,29 mld. |
Biotechnologie & Medisch Onderzoek - Andere
|